Mesoblast Limited (NASDAQ:MESO - Get Free Report)'s stock price fell 7% during trading on Friday . The company traded as low as $12.50 and last traded at $12.37. 32,555 shares changed hands during mid-day trading, a decline of 93% from the average session volume of 437,548 shares. The stock had previously closed at $13.30.
Analyst Upgrades and Downgrades
A number of brokerages have recently commented on MESO. Jefferies Financial Group lowered shares of Mesoblast from a "buy" rating to a "hold" rating in a research report on Monday, December 23rd. Piper Sandler reiterated an "overweight" rating and issued a $24.00 price objective (up from $15.00) on shares of Mesoblast in a research report on Friday, February 7th. Finally, Cantor Fitzgerald raised Mesoblast to a "strong-buy" rating in a research note on Tuesday, March 4th. One analyst has rated the stock with a sell rating, one has given a hold rating, two have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $18.00.
Check Out Our Latest Stock Report on MESO
Mesoblast Trading Down 4.6 %
The stock's 50-day moving average price is $16.21 and its 200-day moving average price is $13.25. The company has a current ratio of 1.18, a quick ratio of 1.18 and a debt-to-equity ratio of 0.21.
Institutional Trading of Mesoblast
Institutional investors have recently made changes to their positions in the company. R Squared Ltd purchased a new position in shares of Mesoblast in the 4th quarter worth about $30,000. Barclays PLC bought a new stake in Mesoblast in the fourth quarter worth about $38,000. Lindbrook Capital LLC boosted its stake in Mesoblast by 70.9% in the fourth quarter. Lindbrook Capital LLC now owns 2,172 shares of the company's stock valued at $43,000 after acquiring an additional 901 shares during the last quarter. JPMorgan Chase & Co. bought a new position in shares of Mesoblast during the 4th quarter valued at approximately $50,000. Finally, BNP Paribas Financial Markets increased its stake in shares of Mesoblast by 86,566.7% during the 4th quarter. BNP Paribas Financial Markets now owns 2,600 shares of the company's stock worth $51,000 after purchasing an additional 2,597 shares during the last quarter. Institutional investors own 1.43% of the company's stock.
About Mesoblast
(
Get Free Report)
Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.
See Also
Before you consider Mesoblast, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Mesoblast wasn't on the list.
While Mesoblast currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
